Mayer Brown represented Irish pharmaceutical company, Adapt Pharma, the distributor of NARCAN® (naloxone HCl) Nasal Spray, in its sale to Emergent BioSolutions Inc. for total consideration of up to $735 million in cash and stock.
NARCAN® is an FDA approved treatment for the reversal of opioid overdose and plays a critical role in responding to the opioid crisis. The acquisition is subject to customary closing conditions, including US antitrust approval, and is expected to close in the fourth quarter of 2018.
The Mayer Brown team was led by New York-based partner Reb Wheeler (Picture).
Involved fees earner: Reb Wheeler – Mayer & Brown;
Law Firms: Mayer & Brown;
Clients: Adapt Pharma;